Larimar Therapeutics, Inc. (LRMR)
Nasdaq · Healthcare · Biotechnology
$2.86−3.38%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $297M
- 52-week range
- $2.72 – $6.42
- 52-week change
- −37.29%
- EPS (trailing)
- −$1.99
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$166M
- Free cash flow
- −$113M
From the company’s annual report on SEC EDGAR.
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Headquarters: Bala Cynwyd, United States · 71 employees · larimartx.com